Researchers have found a way to block the ability of white blood cells to sprint toward the sites of infection when such speed worsens the damage done by sepsis.
An influential cardiologist who criticized an experimental Eli Lilly drug should not have been barred from a panel that evaluated the drug's safety, federal health officials said.
Basilea Pharmaceutica Ltd. announced that the EU Committee for Medicinal Products for Human Use has indicated that the European Commission decision process on Zevtera (ceftobiprole) for the treatment of complicated skin and soft tissue infections is delayed.
Vitamin D may be an important way to arm the immune system against disorders like the common cold.
Research by an Iowa State University scientist suggests that cholesterol-reducing drugs known as statins may lessen brain function.
BioFocus DPI has extended its drug discovery agreement with Eli Lilly and Company until end 2009.
Researchers have developed a new method for producing and studying a type of human papillomavirus (HPV) that causes cervical cancer.
Researchers at Children’s Hospital Boston show that a small protein called lipocalin 2 triggers the EMT in human breast cancer, and that the same protein, when measured in tissues and urine, can predict a cancer's invasiveness.
The Pittcon 2009 Exposition, which takes place March 8-13, McCormick Place South, Chicago, Illinois will showcase 1,000 exhibitors that manufacture, distribute, and market products for laboratory science.
Hybrigenics announced it has signed a substantial contract as part of a large-scale European Union research project called MASTERSWITCH.
Ambrx Inc. and Merck Serono announced a collaboration to develop and commercialize Ambrx’s ARX424 preclinical product candidate for the treatment of multiple sclerosis.
Vaccine manufacturers have substantially increased their capacity to produce pandemic influenza vaccines during the past two years, according to a new study by Oliver Wyman.
Pfizer Inc. said it is ending development of two medicines that had been in final human testing in order to shift funding to other experimental drugs with more potential.
MAP Pharmaceuticals, Inc. announced the results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma.
MDS Analytical Technologies announced that its Arcturus Laser Capture Microdissection (LCM) instruments were used by researchers at the University of Cincinnati in their discovery of genetic variations that may prove to be key predictors of risk for colon cancer.